FDA Inspection 1263799 — Naseem A. Jaffrani, M.D.

Naseem A. Jaffrani, M.D. — FEI 3034993373

The FDA completed an inspection of Naseem A. Jaffrani, M.D. on March 13, 2025 in Alexandria, LA. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 7 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
March 13, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Alexandria, LA (United States)

Additional Details

Clinical Investigator (CI)

Citations

IDCFRDescription
2272721 CFR 312.64(b)Safety Reports - Serious Events
2272821 CFR 312.64(b)Safety Reports - Non-Serious Events
722721 CFR 50.27(a)Consent form not approved/signed/dated
752621 CFR 312.62(a)Accountability records
753021 CFR 312.62(b)Case history records- inadequate or inadequate
755221 CFR 312.66Changes in research
756021 CFR 312.60FD-1572, protocol compliance